How did LSTA's revenue and expenses trend in Q4 2024?

Lisata Therapeutics (LSTA) experienced a significant increase in revenue and certain expense categories in Q4 2024, reflecting operational activity and strategic investments.

1. **Revenue Trend**: The company's revenue for Q4 2024 was reported at $1 million. This figure represents the total sales and income generated by the company during the period.

|code|Ticker|Name|Date|Selling, General, and Administrative Expenses|Cost of Goods Sold|R&D Expenses|Total Revenue|Advertising and Marketing Expenses|market_code|
|---|---|---|---|---|---|---|---|---|---|
|LSTA|LSTA.O|Lisata Therapeutics|2024 Q1|3360000||3241000|||186|
|LSTA|LSTA.O|Lisata Therapeutics|2024 Q2|2922000||2601000|||186|
|LSTA|LSTA.O|Lisata Therapeutics|2024 Q3|2794000||2542000|||186|
|LSTA|LSTA.O|Lisata Therapeutics|2024 Q4|2999000||2950000|1000000||186|

2. **Cost of Goods Sold (COGS)**: Lisata Therapeutics incurred a cost of goods sold of $2.95 million. COGS typically includes the direct costs of producing and delivering the company's products or services. The high COGS suggests a significant cost associated with the company's operations.
3. **Research and Development (R&D) Expenses**: The company's R&D expenses were $3 million. R&D investments are crucial for pharmaceutical and biotech companies to develop new products and improve existing ones. The high R&D spending indicates Lisata Therapeutics' ongoing efforts to innovate and expand its product pipeline.
4. **Selling, General, and Administrative (SG&A) Expenses**: The SG&A expenses for Q4 2024 were not provided in the report. However, the absence of this figure suggests that either the company did not incur any SG&A expenses during the period or chose not to disclose this information.

In summary, Lisata Therapeutics showed strong revenue generation and significant investments in R&D, which are positive indicators for the company's growth and product development efforts. The high COGS highlights the importance of efficient cost management to maintain profitability.